Prefer to read in print? Subscribe for free here
If you would like to feature in the next issue of Pf Magazine, contact us here
January’s articles:
Pf Magazine January 2019 – The state of affairs 2019
Latest articles
NICE recommends ADCETRIS▼ (brentuximab vedotin), in combination with chemotherapy, as frontline treatment for a...
Takeda UK has announced that the National Institute for Health and Care Excellence (NICE) has recommended ADCETRIS (brentuximab vedotin) with cyclophosphamide, doxorubicin and prednisone...
CMA formally concludes fludrocortisone investigation
The Competition and Markets Authority (CMA) has formally concluded its fludrocortison investigation and found that three pharmaceutical companies took part in an illegal arrangement...
MHRA response to Independent Medicines and Medical Devices Safety Review
The Medicines and Healthcare products Regulatory Agency (MHRA) has published its response to the Independent Medicines and Medical Devices Safety Review. In its response, the...
Popular articles
New Normal, New Thinking: Life Post COVID-19
New thinking will be required to adapt to the new normal life post COVID-19. I hate to start this article on a negative note, but...
The ABPI Code & Virtual Promotional Meetings
As the pharma industry looks to virtual meetings and teams work remotely, what considerations are there around the ABPI Code and virtual promotional meetings? Whilst...
First Do No Harm: Independent Medicines and Medical Devices Safety Review publishes its recommendations
The Independent Medicines and Medical Devices Safety Review, chaired by Baroness Julia Cumberlege, has today published its report. Titled 'First Do No Harm', it comes...
Study shows anti-parasitic drug ivermectin kills coronavirus within 48 hours
A collaborative study led by the Monash Biomedicine Discovery Institute (BDI) with the Peter Doherty Institute of Infection and Immunity (Doherty Institute), a joint...
NICE recommends ADCETRIS▼ (brentuximab vedotin), in combination with chemotherapy, as frontline treatment for a...
Takeda UK has announced that the National Institute for Health and Care Excellence (NICE) has recommended ADCETRIS (brentuximab vedotin) with cyclophosphamide, doxorubicin and prednisone...